Key result
Functional class III/IV DCM linked to ~172% higher annual societal costs versus less symptomatic disease.
Why the study?
Dilated cardiomyopathy is a major cause of heart failure impairing patient wellbeing and imposing a substantial economic burden on society, but respective data on quality of life and societal costs are missing.
Cross-Sectional (n=550)
Dilated cardiomyopathy imposes a substantial economic burden and reduces quality of life, particularly in patients with more severe symptoms (NYHA class III/IV).
Answers are grounded in this paper and cite their sources.
Symptomatic DCM links to higher societal costs; cross-sectional data leaves open causal links and intervention effects.
AIMS: Dilated cardiomyopathy (DCM) is a major cause of heart failure impairing patient wellbeing and imposing a substantial economic burden on society, but respective data are missing. This study aims to measure the quality of life (QoL) and societal costs of DCM patients. METHODS AND RESULTS: A cross-sectional evaluation of QoL and societal costs of DCM patients was performed through the 5-level EuroQol and the Medical Consumption Questionnaire and Productivity Cost Questionnaire, respectively. QoL was translated into numerical values (i.e. utilities). Costs were measured from a Dutch societal perspective. Final costs were extrapolated to 1 year, reported in 2022 Euros, and compared between DCM severity according to NYHA classes. A total of 550 DCM patients from the Maastricht cardiomyopathy registry were included. Mean age was 61 years, and 34% were women. Overall utility was slightly lower for DCM patients than the population mean (0.840 vs. 0.869, P = 0.225). Among EQ-5D dimensions, DCM patients scored lowest in 'usual activities'. Total societal DCM costs were €14 843 per patient per year. Cost drivers were productivity losses (€7037) and medical costs (€4621). Patients with more symptomatic DCM (i.e. NYHA class III or IV) had significantly higher average DCM costs per year compared to less symptomatic DCM (€31 099 vs. €11 446, P < 0.001) and significantly lower utilities (0.631 vs. 0.883, P < 0.001). CONCLUSION: DCM is associated with high societal costs and reduced QoL, in particular with high DCM severity.
No takes yet. Share an insight, caveat, or question.
Wiethoff et al. (2023) conducted a cross-sectional in Dilated cardiomyopathy (n=550). More symptomatic DCM (NYHA class III or IV) vs. Less symptomatic DCM was evaluated on Average societal DCM costs per year (p=<0.001). More symptomatic dilated cardiomyopathy (functional class III/IV) was associated with higher average societal costs per year compared to less symptomatic disease.
Synapse has enriched 10 related papers. Consider them for comparative context: